Becoming both a pharma and a tech company

Rubrik: GMP / GLP / GCP

(Treffer aus pharmind, Nr. 08, Seite 721 (2023))

Schrader U

Becoming both a pharma and a tech company / How to drive value in biopharma by scaling digital capabilities · Schrader U · McKinsey, Hamburg
The impact of the global chip crisis has seen car production fall by 18 %. Within the same timeframe though, Tesla increased its output by 25 %. How did they do this? The answers are technology competence and vertical integration. Tesla set themselves apart from the rest of the car industry with their inhouse capabilities in digital and artificial intelligence (AI) as well as hardware engineering. They are as much a tech company as they are a car maker. So, how relevant is this dual status beyond managing through the chip crisis? Certainly, it is important from the point of view of ...

Operations Can Launch the Next Blockbuster in Pharma

Rubrik: IT

(Treffer aus pharmind, Nr. 12, Seite 1625 (2020))

Schrader U

Operations Can Launch the Next Blockbuster in Pharma / Schrader • Operations in Pharma · Schrader U · McKinsey, Hamburg
Most of the time, imagining the future involves little more than linear extrapolation – noting where we are now, the path taken to get here, and simply extending. But what if we put ourselves in the mindset of a Steve Jobs (Apple) or Elon Musk (Tesla) or Jack Ma (Alibaba)? How would they set up pharma manufacturing and supply? What would a more radical imagining look like? Let’s give it a try with a few potential hallmarks of future pharma operations. Pharma is a highly regulated industry and we spend approximately 30 % of our time on various documentation-related activities: product ...

Der Produktionsstandort Deutschland

Rubrik: Fachthemen

(Treffer aus pharmind, Nr. 04, Seite 468 (2015))

Schrader U | Gerstner W

Der Produktionsstandort Deutschland / Deutschland muss sich stärker für den Wettbewerb rüsten · Schrader U, Gerstner W · McKinsey & Company, Hamburg
Noch immer ist Deutschland weltweit einer der wichtigsten Produktionsstandorte für pharmazeutische Produkte. Doch wachsende Konkurrenz aus dem Ausland gefährdet die starke Position. Eine erstmals für den Standort Deutschland durchgeführte McKinsey-Benchmarking-Analyse zeigt, wie sich hiesige Werke am besten im internationalen Wettbewerb behaupten können.